Lunai Bioworks Company Description
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands.
It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
It also develops BioSymetrics platform, for multi-omics integration for target identification and validation; clinical trial optimization, including patient stratification and response monitoring; and screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics.
The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025.
Lunai Bioworks Inc. is based in Sacramento, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | David Weinstein |
Contact Details
Address: 3400 Cottage Way Sacramento, California 95825 United States | |
| Phone | (424) 222-9301 |
| Website | lunaibioworks.com |
Stock Details
| Ticker Symbol | LNAI |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| ISIN Number | US29350E3027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David H. Weinstein | Chief Executive Officer and Director |